Earnings Releases·Nov 10, 2026, 4:03 PM ET

Bionano Genomics — Q3 2026 Earnings Summary

Total revenue rose 12% year-over-year to $8.3 million, driven by a 24% increase in consumables revenue to $4.7 million, while net loss narrowed to $6.5 million from $8.5 million in the prior year period.
The company reiterated full-year 2026 revenue guidance of $31 million to $33 million and expects momentum to translate into sustained growth in 2027, supported by clearer reimbursement pathways for OGM-based testing.
Balance sheet improvements include the elimination of $10.0 million in convertible debentures and an increase in cash and cash equivalents to $4.4 million, though total current assets declined to $25.5 million from $45.4 million at year-end 2025.
Strategic progress includes three new peer-reviewed publications validating OGM clinical value, expanded state-level approvals for third-party tests, and continued integration of OGM into leading academic cancer centers.
Management highlights risks regarding the need to extend cash runway, achieve profitability, and secure additional financing to avoid potential insolvency proceedings, alongside exposure to macroeconomic and geopolitical headwinds.